VANCOUVER, BC / ACCESS Newswire / January 16, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its ...

KENNESAW, GA / ACCESS Newswire / January 16, 2025 / At BenCura, continuous education and quality improvement form the cornerstone of our organization. In line with this commitment, we are excited to ...

TAMPA, FLORIDA / ACCESS Newswire / January 16, 2025 / ModMed continues to dominate the field of physician practice electronic health record (EHR) software, earning top honors in the 2025 Black Book ...

Targeting Formula to Enhance Muscle Growth, Repair, and Endurance MADRID, SPAIN / ACCESS Newswire / January 16, 2025 / Veos Pharmaceuticals, a leading innovator with a portfolio of nearly 40 products ...

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new ...

Oxford Drug Design, the Oxford-based AI drug discovery company, has today announced additional in vivo validation for its first-in-class approach against cancer as the Company continues to apply its ...

PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa ...

Cellev8's Brand Expands Beyond Consumers  WELLINGTON, FLORIDA / ACCESSWIRE / January 15, 2025 / Cellev8 Nutrition Inc., a leader in natural health supplements, is proud to announce an exclusive ...

Comprehensive Gratis Report Featuring Profiles and Client Engagement Ratings for 260 HIT Consulting and Advisory Firms TAMPA, FLORIDA / ACCESSWIRE / January 15, 2025 / Black Book Research announces ...

Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design ...

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the ...

Forecast for 2025 For the current fiscal year, Dräger expects an increase in net sales of 1.0 to 5.0 percent (net of currency effects) and an EBIT margin of 3.5 to 6.5 percent. The expected EBIT ...